Jefferies Raises HOLX Estimates

Jefferies is making some adjustments to its Hologic HOLX estimates. “We are increasing our F11 revenue estimate to $1,769M, from $1,750M, as well as our F11 pro-forma EPS estimate to $1.23, from $1.22. F11 consensus revenue and EPS currently stands at $1,755M and $1.23,” Jefferies writes. “In addition, we are raising our F12 revenue and pro-forma EPS estimates to $1,941M and $1.45, from $1,875M and $1.40, respectively. F12 consensus revenue and EPS resides at $1,854.9M and $1.35, respectively. “We believe that our estimates bake in significant conservatism as ASPs could be as high as $450K per system and the adoption ramp could be much higher than the assumptions in our model.” Hologic closed Friday at $20.18.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsHealth CareHealth Care EquipmenthologicJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!